07:30 am

Registration and Morning coffee

08:15 am

Welcome and Introductory Remarks
CCS President - Andrew Judge, University of Florida, USA
Local Co-Host - Paola Costelli, University of Turin, Italy

Insights into cancer cachexia from the TRACERx lung study
Mariam Jamal-Hanjani, UCL Cancer Institute, UK

Integrative programs in patients with Lung Cancer
Silvia Novello, University of Turin, Italy

The transcriptomic landscape of human pancreatic cancer-associated cachexia
Jenny Permuth, Moffitt Cancer Center, USA

Serum miRNA signatures in cancer cachexia depends on systemic inflammation
Terese Louise Schmidberger Karlsen, NTNU, Norway

Cytokines involved in cachexia in mice and patients with non-small cell lung cancer
Cristina Munoz-Pinedo, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Spain 

Loss of skeletal muscle mass associates with poor survival and reduced cytotoxic T-cells in advanced lung cancer
Yan Sun, Maastricht university, Netherlands 

COFFEE BREAK

Spatiotemporal Metabolic Networks in Pancreatic Cancer and associated Cachexia
Nada Kalaany, Harvard Medical School, Boston Children's Hospital, USA

Changes in fibroblast composition promote pancreatic cancer-associated cachexia
Giulia Biffi, University of Cambridge, UK

Systemic influence of metastasis in cachexia
Salvador Aznar Benitah, ICREA Research Professor, IRB Barcelona, Spain

Tumour-borne ADAMTSL4 drives cancer cachexia via activation of the TGFbeta signalling pathway
Juliano Machado, Helmholtz Diabetes Center. Institute for Diabetes and Cancer, Germany

Muscle-tumor crosstalk in metastasis dissemination
Paolo Porporato, University of Turin, Italy

Pancreatic cancer cachexia is mediated by tumor-derived PTHrP
Jason Pitarresi, University of Massachusetts Chan Medical School, USA

LUNCH BREAK 

Meet A Mentor

01:00 pm - 02:30 pm
Session C: Metabolic and Tissue Crosstalk in Cancer Cachexia
Chairs: Silvia Busquets, University of Barcelona, Spain;
            Laure Bindels, Université catholique de Louvain, Belgium

Identifying a new spatio-temporal coordinated response to cancer
Maria Rohm, Helmholtz Center Munich, Germany

Role of the liver-gut-muscle axis in the pathogenesis of cancer cachexia
Andrea Bonetto, University of Colorado Anschutz Medical Campus, USA

Exploring the Role of Insulin Resistance in Cancer Cachexia
Lykke Sylow, University of Copenhagen, Denmark 

Genomic Profiling identifies hepatocyte-secreted factors that contribute to tissue wasting in cancer cachexia
Doris Kaltenecker, Insitute for Diabetes and Cancer, Helmholtz Munich, Germany 

A New Role for an Old Drug: Zoledronate as a Dual Agent Against Stemness and Cachexia in Ovarian Cancer
Fabrizio Pin, Indiana University School of Medicine, USA 

Machine Learning-Based Stratification of Cachexia Stages in a Murine Model Uncovers Multi-Tissue Transcriptomic Signatures
Robson Carvalho, Sao Paulo State University (UNESP), Brazil 

02:35 pm - 03:00 pm
Session D: Next Gen I
Chairs: Ross Dolan, University of Glasgow, UK;
           Daria Neyroud, University of Lausanne, Switzerland

IL-1beta Signaling Through MyD88 Drives Pro-Cachectic Suppressive Neutrophil Infiltration in Skeletal and Cardiac Muscle
Blake Roberts, University of Alberta, Canada 

Pancreatic Tumor Organoid Factors Induce Lipid Accumulation in Skeletal Muscle Cells from Individuals with Type 2 Diabetes and Alter Mitochondrial Function in Cachexia
Lara Stassen, Maastricht University, Netherlands

Targeting Metastasis to Combat Cancer-Associated Cachexia: Unraveling the Role of Host Metabolism in Metastasis and Cachexia Progression
Blanca Majem, Biomedical Research Institute of Barcelona, Spain 

Beyond Starvation: Exploring Hypermetabolism in Incurable Cancer
Marianne Erichsen, UiT The Arctic University of Norway, Norway

Bile acid dysregulation promotes cachexia in YAP-driven liver cancer
Madeline Webb, Peter Macallum Cancer Centre, Australia

COFFEE BREAK AND POSTER VIEWING

04:30 pm - 05:30 pm 
Session E: Kenneth CH Fearon Keynote Lectureship

Introduction: Fabio Penna, Italy
Keynote Speaker: Paola Costelli, Italy

05:30 - 07:00 pm
Welcome Reception - Aldo Moro

 Morning Reflective Walk
Piazza Castello to Aldo Moro (0.5m/0.8km; ~10-15 min)

Please wear your conference t-shirt and join us for a reflective walk, as a quiet and meaningful way to honor those affected by cancer cachexia. Together we will take steps – literally and symbolically – towards raising awareness!

Meet at Piazza Castello at 07:20, for a 7:30 departure.

Registration and Morning Coffee

Early Promise, Early Access: Advancing Central Melanocortin Receptor
Antagonists for Cancer Cachexia
Meghan Joly, PhD, Lead Clinical Scientist, Endevica Bio

09:00 am - 10:00 am 
Session F: Central Regulation Systems of Feeding and Metabolism
Chairs: Mauricio Berriel Diaz, Helmholtz Center Munich, Germany;
           Vera Mazurak, University of Alberta, Canada

Brain-body connections during cancer progression
Tobias Janowitz, Cold Spring Harbor Laboratory, USA

Understanding the control of appetite in health and disease
Anthony Coll, University of Cambridge, UK

The GDF15-GFRAL axis elevates the metabolic rate and muscle lipid
oxidation in cancer cachexia via the beta-adrenergic system
Steffen Raun, University of Copenhagen, Denmark

Race- and sex-based differences in serum biomarkers for cancer-
associated cachexia in a diverse cohort of patients with pancreatic
ductal adenocarcinoma
Margaret Park, Moffit Cancer Center, USA

10:30 am - 12:00 pm 
Session G: Cancer-Induced Muscle Wasting and Associated Muscle Pathologies
Chairs: Roberta Sartori, University of Padova, Italy;
           Sarah Judge, University of Florida, USA

10:30 am

Cardiac wasting in cancer – the problem, the clinical implications
Stefan Anker, Charite, Germany

10:52 am

Whac-a-Mole or Occam’s Razor? Mechanisms of muscle loss in
pancreatic cancer cachexia
Teresa Zimmers, Oregon Health & Science University, USA

11:14 am

Dissecting the gene networks that control cachexia for developing a
combinatorial RNA-based therapy
Marco Sandri, Veneto Institute of Molecular Medicine, Dept Biomedical
Sciences, University of Padova, Italy

11:36 am

Oxytocin counteracts muscle wasting and rescues muscle metabolism
Dario Coletti, Sapienza University of Rome, Italy 

11:44 am

Ajay Rana, University of Illinois at Chicago, USA 

11:52 am

in skeletal muscle during cancer cachexia
Elia Angelino, Università del Piemonte Orientale, Italy

12:00 pm

Andreas Fischer, Göttingen University Medical Center, Germany

12:10 pm

12.25 pm

12:25 pm

Industry Symposium
Actimed Therapeutics

01:15 pm - 02:40 pm

Session H: Lifestyle Interventions for Cancer Cachexia
Chairs: Trude Rakel Balstad, Norwegian University of Science and Technology, Norway; 
           Calvin Cole, University of Rochester, USA

01:15 pm

Beyond Calories: Precision Nutrition in Cancer Cachexia
Paula Ravasco, Faculty of Medicine, Universidade Católica Portuguesa,
Portugal

01:37 pm

Multimodal interventions for cancer cachexia: where are we now 
Matthew Maddocks, King's College London, UK

01:59 pm

Exercise interventions to improve body composition in cancer
survivors
Anouk Hiensch, University Medical Center Utrecht, Netherlands 

02:21 pm

Promising effects of muscle stimulation for function, muscle mass,
and quality of life during stem cell transplant for hematologic
malignancies
Lindsey Anderson, VA Puget Sound Health Care System, USA

02:29 pm

Can cachexia severity predict physical function phenotypes?
Ishan Roy, Shirley Ryan AbilityLab & Northwestern University, USA

02:37 pm

Features of cachexia in patients with ovarian cancer and impact on
performance in a structured oncologic exercise program
Leah Novinger, University of Colorado, USA

02:45 pm - 03:10 pm
Session I: Next Gen II
Chairs: Brittany Counts, Oregon Health & Science University, USA;
           Paige Arneson-Wissink, Oregon Health & Science University, USA

02:45 pm

Repurposing Dasatinib: A Novel Strategy to Attenuate Cancer
Associated Cachexia
Sai Vara Prasad Chitti, La Trobe University, Australia

02:50 pm

Does cachexia hinder the recognized benefits of physical activity in
cancer patients?
Romane Peyrachon, Rennes 2 University M2S Lab, France

02:55 pm

Pancreatic Enzyme Dysregulation in Cancer Cachexia: A Paradox of Insufficiency and Overactivity
Tuna Felix Samanci, Helmholtz Munich, Germany 

03:00 pm

Primary-stage colon cancer impairs muscle energy metabolism by
suppressing mitochondrial complex I activity
Xiaolin Li, Wageningen University & Research, Netherlands

03:05 pm

Cancer-associated cachexia (CAC) rewires cholesterol metabolism to
support tumorigenesis
Naama Darzi, Weizmann Institute of Science, Israel

03:10 pm

 04:40 pm - 06:00 pm
Session J:  Funding, Publishing & Regulatory Aspects of Cancer Cachexia
Chairs: Mariam Jamal-Hanjani, UCL Cancer Institute, UK
           Jose Garcia, University of Washington, USA

04:40 pm

Cancer Grand Challenges: The Cachexia Grand Challenge.
Gemma Balmer-Kemp, Cancer Research, UK - Cancer Grand Challenges

05:05 pm

Key regulatory considerations in cancer cachexia
Naomi Lowy, Principal Drug Regulatory Expert, Hyman, Phelps &
McNamara, P.C, USA – Regulatory Aspects of Cancer Cachexia Trials

05:30 pm

Meet the Editor Panel Discussion:
Revati Dewal (Nature Metabolism)
Maria Garcia-Fernandez (Nature Communications)
Stefan Anker (J Cachexia Sarcopenia Muscle)

06:00 pm

 06:45 - 09:30 pm
Apericena al Rettorato - Palazzo del Rettorato

07:30 am

Registration and Morning coffee

Session K: Emerging and Understudied Topics in Cancer Cachexia
Chairs: Sander Rensen, Maastricht University, Netherlands;
            Erin Talbert, University of Iowa, USA

Smaller Patients, Bigger Challenges? Advances in Childhood Cancer
Cachexia
Daniel Runco, Seattle Children's Hospital, USA - Pediatric Cancer Cachexia

Towards an Understanding of Cancer Cachexia Subtypes: Data from the
CANCAN Uncover Study
Bette Caan, Kaiser Permanente Northern California, Division of Research,
USA - Identification of Cachexia Subtypes

Contemplating contributing factors in cachexia
Paul Gregorevic, University of Melbourne, Australia

NMJ Dysregulation in Human Cancer Cachexia: Fact or Fiction?
Richard Skipworth, Royal Infirmary of Edinburgh/University of Edinburgh
UK

NMJ Q&A Discussion
Paul Gregorevic and Richard Skipworth

Pancreatic cancer promotes cardiac dysfunction through altered
adrenergic signaling in the heart
Aaron Grossberg, Oregon Health & Science University, USA

Neuromuscular organoids mimic cancer induced muscle cachexia
Anna Urciuolo, University of Padova, Italy

COFFEE BREAK

Session L: NODES Session - Current Management of Cancer Cachexia
Chairs: Martin Kochanczyk, Cancer Cachexia Network Co-Chair;
           Marcus Goncalves, NYU Grossman School of Medicine, USA

Cancer Patient Perspective on Cachexia

Caregiver Perspective on Cachexia

Patient Organization Perspective on Cachexia
Stefania Vallone, Women Against Lung Cancer in Europe

What People Talk About When They Talk About Cachexia
Martin Kochanczyk, Cancer Cachexia Network Co-Chair

Cancer Cachexia Care: Perspectives from New York and Beyond
Marcus Goncalves, NYU Grossman School of Medicine, USA

The metabolic side of cancer cachexia: an endocrinologist’s perspective
Jose Garcia, University of Washington, USA

Thinking about function: the role of physiotherapy in cachexia care
Matthew Maddocks, King's College London, UK

Nutrition-Centered Strategies for Improving Outcomes in Cancer
Cachexia
Paula Ravasco, Faculty of Medicine, Universidade Católica Portuguesa,
Portugal

surgeon’s perspective
Steven Olde Damink, Maastrict University, Netherland

Eric Roeland, Oregon Health and Sciences University, Knight Cancer
Institute, USA

LUNCH BREAK 

Meet A Mentor

12:45 pm - 03:05 pm
Session M: Clinical Trial Updates
Chairs: Barry Laird, University of Oslo, Norway;
            Tora Skeidsvoll Solheim, Norwegian University of Science and Technology, Norway

12:45 pm

Clinical Development of Mifomelatide
Jillian L. Seiler, PhD, Senior Scientist, Endevica Bio

01:05 pm

GDF-15 blockade - A multi-directional approach to potentiate cancer
immunotherapy and alleviate cancer cachexia: The visugromab
experience
Gabriel Fox, Dr, Clinical Development Consultant, CatalYm

01:25 pm

01:45 pm

Ponsegromab cancer cachexia clinical trial update
Eric Roeland, Oregon Health and Sciences University, Knight Cancer Institute, USA

02:05 pm

Interim analysis of the Phase 2 Cancer Appetite Recovery Study evaluating ART27.13, a peripherally selective synthetic cannabinoid agonist
Barry Laird, University of Oslo, Norway

02:25 pm

Actimed Clinical Development of S-pindolol benzoate for Cancer
Cachexia and Muscle Wasting Disorders
Fabio Dorigotti, Chief Medical Officer, Actimed

02:45 pm

The Real-world Evidence of Anamorelin in Japan: First-in-Class, Lasting Lessons
Tateaki Naito, Shizuoka Cancer Center, Japan - Anamorelin

03:05 pm

03:30 pm - 04:14 pm
Session N: ESPEN and MASCC
Chair: Maurizio Muscaritoli, Sapienza University of Rome, Italy

Jan Arends, Universitätsklinik Freiburg, Germany 

Advancing Best Supportive Care in Cachexia: MASCC Tackling Nutrition Impact Symptoms
Tateaki Naito, Shizuoka Cancer Center, Japan 

04:14 pm - 05:00 pm
Session O: Late Breaking
Chairs: Eija Pirinen, University of Oulu, Finland
           Xavier Clemente-Casares, University of Alberta, Canada

Josh Huot, Indiana University School of Medicine, USA

04:21 pm 

Bert Blaauw, Veneto Institute of Molecular Medicine, Dept Biomedical
Sciences, University of Padova, Italy

mitochondrial stress and interferon response
Katarzyna Whysall, University of Galway, Ireland

Therapeutic Treatment Target for Pancreatic Cancer-Associated Skeletal
Muscle Wasting
Calvin Cole, University of Rochester, USA

Serum amyloid protein A1 (SAA1) impairs myogenesis and myofiber size
in pancreatic cancer cachexia
Gabriele Guarnaccia, Sanford Burnham Prebys Medical Discovery Institute,
USA

Denis Guttridge, Medical University of South Carolina, USA